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Increased bradykinin and “normal” angiotensin peptide levels experimental animals [1–7] suggest altered humoral con-
in diabetic Sprague Dawley and transgenic (mRen-2)27 rats. trol of microvascular function. Several lines of evidence
Background. The transgenic (mRen-2)27 rat (TGR) is a suggest a role for bradykinin (BK) and angiotensinhigh tissue renin, high angiotensin (Ang) II model of hyperten-
(Ang) peptides in the pathogenesis of diabetic lesions.sion. When administered streptozotocin (STZ), TGRs develop
BK is a potent endothelium-dependent vasodilator thata rapidly progressive diabetic nephropathy with renal failure
over 12 weeks. Bradykinin (BK) and Ang II are potent vaso- increases vascular permeability and plays a primary role
active peptides that may participate in the vascular and meta- in inflammation [8], whereas Ang II has many actions,
bolic abnormalities of diabetes. including vasoconstriction, causing an increase in intra-Methods. TGR and Sprague-Dawley (SD) rats were admin-
glomerular capillary pressure [9] and stimulation of cyto-istered STZ (diabetic) or citrate buffer (nondiabetic) at six
kine production and vascular hypertrophy [10].weeks of age. Diabetic rats received daily ultralente insulin
to maintain moderate hyperglycemia (z18 mm). Rats were Genetic evidence for a role of BK and Ang peptides
sacrificed four- and eight-weeks post-STZ or vehicle. in diabetic renal disease includes reports that polymor-
Results. Diabetes did not modify the blood pressure of either
phisms of the angiotensin converting enzyme (ACE) andSD rats or TGRs. Diabetes increased levels of BK-(1-9) and
angiotensinogen genes contribute to the development ofits metabolite BK-(1-7) in kidney, aorta, and heart of both SD
rats and TGRs. Diabetes did not influence Ang II levels in renal complications in insulin-dependent diabetes melli-
plasma, kidney, aorta, heart, or adrenal gland of SD rats, but tus (IDDM) in humans [11, 12]. Pharmacological evi-
reduced to normal the elevated Ang II levels in plasma, kidney, dence for a role for BK and Ang II in diabetic vascular
aorta, and adrenal gland of TGRs.
disease and nephropathy includes the reduction of vascu-Conclusions. STZ-induced diabetes was associated with ele-
lar hypertrophy, the improvement of endothelial func-vated tissue levels of BK-(1-9) and “normal” circulating and
tissue levels of Ang II. The increased BK-(1-9) levels were tion, and the renoprotective effects of ACE inhibitors
consistent with the participation of this peptide in the vascular in both subjects with diabetes [13–15] and animal models
and metabolic abnormalities of diabetes. However, the rapidly of diabetic nephropathy [16–18]. Additionally, antago-progressive nephropathy of diabetic TGRs was not associated
nists of the type 1 Ang II (AT1) receptor have renopro-with BK-(1-9) and Ang II levels in target organs that differed
tective and antihypertrophic actions in diabetes [17, 18].from those of diabetic SD rats.
We investigated the hypothesis that Ang and BK pep-
tide levels are altered in diabetes by measuring circulat-
ing levels of Ang peptides and tissue levels of Ang andDiabetes evokes a complex series of events that results
BK peptides in rats with streptozotocin (STZ)-inducedin structural and functional abnormalities in many tis-
sues, including the kidney and the cardiovascular system. diabetes. We studied both Sprague-Dawley (SD) and
Glomerular hyperfiltration, increased glomerular plasma transgenic (mRen-2)27 rats (TGRs). TGRs are SD rats
flow, and an elevated glomerular capillary hydraulic pres- transgenic for the mouse Ren-2 gene. This is a high tissue
sure of early insulin-dependent diabetes in humans and renin, high Ang II model of hypertension [19]. When
administered STZ, TGRs develop a rapidly progressive
diabetic nephropathy [20]. An aim of this study was toKey words: hypertension, prorenin, angiotensin converting enzyme,
endopeptidase, diabetic nephropathy. determine whether the accelerated glomerulosclerosis of
TGRs is associated with increased renal Ang II levels.Received for publication November 17, 1998
Albuminuria increases progressively over 12 weeks inand in revised form February 9, 1999
Accepted for publication February 12, 1999 diabetic TGRs, and the glomerular filtration rate (GFR)
is increased at four and eight weeks and then subse- 1999 by the International Society of Nephrology
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quently declines [20]. The most florid renal lesions occur (1 to 2 ml) was immediately extracted with Sep-Pak C18
cartridges (Waters Chromatography Division, Milford,after 12 weeks of diabetes in TGRs, with no morphologi-
cal changes evident at four weeks and only basement MA, USA). Ang peptides were acetylated and piperidine
treated before high-performance liquid chromatographymembrane thickening evident at eight weeks (unpub-
lished data from this laboratory) [20]. In the current (HPLC) and assay of HPLC fractions by N-terminal–
directed radioimmunoassay (RIA) [21, 23]. Data werestudy, rats were studied after four and eight weeks of
diabetes, because this represents the time of develop- corrected for recovery as reported elsewhere [21].
Tissues homogenized in GTC/TFA were processed asment of the renal lesion in diabetic TGRs.
described previously [24] before acetylation and piperi-
dine treatment and HPLC and measurement of Ang and
METHODS
BK peptides by N-terminal–directed RIA [21, 24]. Data
Animals were corrected for recovery as reported elsewhere [21, 24].
Diabetes was induced in six-week-old female SD rats
Renin, prorenin, angiotensinogen,and heterozygous TGRs by the administration of 55 mg/kg
angiotensin converting enzyme,STZ (Sigma, St. Louis, MO, USA) diluted in 0.1 m citrate
and neutral endopeptidase 24.11 assaysbuffer, pH 4.5, by tail vein injection following an over-
night fast. Nondiabetic rats were injected with citrate Trunk blood for the measurement of renin, prorenin,
angiotensinogen, ACE, and NEP was collected into hep-buffer alone. All rats were allowed free access to tap
water and standard rat chow containing 0.25% sodium arinized tubes on ice and then centrifuged, and the plasma
was rapidly frozen on dry ice and stored at 2808C. Theand 0.76% potassium (GR2; Clarke-King & Co., Glades-
ville, NSW, Australia). Each week, rats were weighed plasma concentrations of active renin, prorenin, and an-
giotensinogen were measured as described previouslyand blood glucose (control, 4 to 8 mm; diabetic, more
than 18 mm) was estimated using an AMES glucometer [19, 25]. Renin and prorenin activities were expressed as
Goldblatt units per milliliter, using hog renin as reference(Bayer Diagnostics, Melbourne, Victoria, Australia).
Systolic blood pressure was recorded in conscious rats by standard (National Standards Laboratory, Holly Hill,
London, UK). ACE enzymatic activity was measured astail cuff plethysmography (model PE-300 programmed
electrosphygmanometer; Narco Bio-Systems, Inc., Aus- described by Friedland and Silverstein [26], and NEP
enzymatic activity was measured as described by Yandletin, TX, USA). Diabetic rats received daily intraperito-
neal injections of insulin (two to four units; Ultratard, et al [27].
Novo Nordisk, Denmark). Experimental procedures ad-
Statisticshered to the guidelines of the National Health and Medi-
cal Research Council of Australia’s Code for the Care Data are presented as means 6 sem. Peptide ratios were
calculated for individual rats, and the ratios are also pre-and Use of Animals for Scientific Purposes and were
approved by the Bioethics Committee of the University sented as means 6 sem. Data were analyzed by unpaired
t-test and by analysis of variance. The effects of diabetesof Melbourne.
At four- and eight-weeks post-STZ or vehicle, rats were were analyzed at four- and eight-weeks post-STZ in SD
rats and TGRs separately. In addition, TGRs were com-killed by decapitation. Trunk blood was collected for the
measurement of plasma levels of renin, angiotensinogen, pared with SD rats of the same age. Logarithmic transfor-
mation of the data was performed when required toACE, neutral endopeptidase 24.11 (NEP), and Ang pep-
tides, and the left kidney, adrenal glands, heart (cardiac obtain similar variances between groups. Differences
were considered significant at a P of less than 0.05. Sta-ventricles) and aorta were rapidly removed, weighed,
and immediately homogenized in 4 m guanidine thiocya- tistical analyses were performed using SuperANOVAt
(Abacus Concepts, Inc., Berkeley, CA, USA).nate, 1% trifluoroacetic acid in water (GTC/TFA) for the
measurement of tissue levels of Ang and BK peptides.
RESULTSAngiotensin and bradykinin peptide assay
Blood pressure, body weight, heart weight,Plasma levels of Ang II and its biologically inactive pre-
and kidney weightcursor Ang I were measured as described previously [21].
Briefly, trunk blood (2 to 3 ml) was rapidly collected into Nondiabetic TGRs were hypertensive and had cardiac
hypertrophy (Table 1). Nondiabetic TGRs had a lowertubes containing 0.5 ml inhibitor solution (1 mm renin
inhibitor acetyl-His-Pro-Phe-Val-Sta-Leu-Phe-NH2 [22], body weight than nondiabetic SD rats at four weeks but
not at eight weeks postvehicle. Additionally, nondiabetic146 mm pepstatin, 50 mm 1,10-phenanthroline, 125 mm
ethylenediaminetetraacetic acid (EDTA), 2 g/liter neo- TGRs had higher kidney weight/body weight ratios than
nondiabetic SD rats at four weeks (Table 1). Diabetesmycin sulfate, 2% dimethyl sulfoxide, and 2% ethanol in
water) at 48C. The blood was centrifuged, and the plasma had no effect on the blood pressure of either SD rats or
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Table 1. Blood pressure, body weight, and tissue weights of non-diabetic and diabetic SD rats and TGR
Duration of diabetes weeks
4 8
Parameter SD TGR SD TGR
Systolic blood pressure mm Hg
Non-diabetic 11866 150 62d 10862 15266d
Diabetic 10662 155 64d 11664 15164d
Body weight g
Non-diabetic 29865 266 65d 283611 275614
Diabetic 24768b 229614a 222611b 21367b
Heart weight mg
Non-diabetic 860623 899 622 848618 1064646d
Diabetic 758640a 764668 751626b 781630b
Heart weight/body weight ratio mg/g
Non-diabetic 2.8860.04 3.40 60.10d 3.0360.13 3.8860.12d
Diabetic 3.0760.14 3.31 60.13 3.4460.18 3.7060.17
Left kidney weight mg
Non-diabetic 1097622 1089 618 1041621 1033647
Diabetic 1257632b 1457676b,c 1565659b 1504655b
Left kidney weight/body weight ratio mg/g
Non-diabetic 3.6860.05 4.11 60.10d 3.7260.15 3.7760.10
Diabetic 5.1660.24b 6.6260.51b,c 7.1460.31b 7.1760.41b
Values are expressed as means 6 sem; N 5 6 to 10. Abbreviations are: Sprague Dawley (SD), transgenic m(Ren-2)27 rat (TGR).
a P , 0.05, b P , 0.01, in comparison with respective non-diabetic group of the same duration
c P , 0.05, d P , 0.01, in comparison with respective SD rats of the same duration
TGRs. In comparison with the corresponding nondia- TGRs than in diabetic SD rats (Table 2). Diabetic rats
had lower plasma angiotensinogen levels than nondia-betic rats, diabetic rats had a reduced body weight. There
were no differences between body weights of diabetic betic rats at eight weeks in SD rats and at both four and
eight weeks in TGRs. Nondiabetic SD rats and TGRsSD rats and TGRs, and the heart weights and heart
weight/body weight ratios of diabetic SD rats and TGRs had similar plasma ACE levels at four weeks, but at
eight weeks, plasma ACE levels of nondiabetic TGRswere similar (Table 1). Diabetic SD rats and TGRs had
higher kidney weights and kidney weight/body weight were lower than those of nondiabetic SD rats (Table 2).
Diabetes increased plasma ACE levels at four weeks inratios than the corresponding nondiabetic rats. Both the
kidney weight and the kidney weight/body weight ratio SD rats and at eight weeks in TGRs. Thus, at four weeks,
plasma ACE levels of diabetic SD rats were higher thanwere increased in diabetic TGRs compared with diabetic
SD rats at four weeks but not at eight weeks (Table 1). those of diabetic TGRs, whereas at eight weeks, plasma
ACE levels of diabetic TGRs were higher than those of
Plasma glucose, renin, prorenin, angiotensinogen, diabetic SD rats (Table 2). SD rats and TGRs did not
angiotensin converting enzyme, and differ with respect to plasma NEP levels, and diabetes
neutral endopeptidase 24.11 had no effect on these levels (Table 2).
Plasma glucose levels were similar for SD rats and
Plasma angiotensin peptidesTGRs and were approximately threefold higher in dia-
betic animals (Table 2). Plasma renin levels were 1.6- to In agreement with their increased renin levels, nondia-
betic TGRs had higher plasma Ang II and Ang I levels4-fold higher in TGRs than in SD rats for both nondia-
betic rats at four and eight weeks and for diabetic rats than nondiabetic SD rats at both four and eight weeks
(Fig. 1). The Ang II/Ang I ratio provides an index ofat eight weeks. Prorenin levels were 37- to 61-fold higher
in both nondiabetic and diabetic TGRs than in SD rats, the rate of conversion of Ang I to Ang II. Nondiabetic
TGRs had a lower Ang II/Ang I ratio than nondiabeticwith a corresponding increase in the prorenin/total renin
ratio in TGRs (Table 2). Diabetes was without effect on SD rats at four and eight weeks, in agreement with the
lower plasma ACE levels in nondiabetic TGRs than inrenin and prorenin levels at four weeks. At eight weeks,
prorenin levels were 2.9-fold higher in diabetic than non- nondiabetic SD rats at eight weeks (Table 2). Diabetes
had no effect on plasma Ang peptide levels in SD rats,diabetic SD rats and 2.6-fold higher in diabetic than
nondiabetic TGRs. However, diabetes did not affect the but reduced Ang II and Ang I levels at four weeks and
Ang II levels at eight weeks in TGRs. Thus, the plasmaprorenin/total renin ratio. Plasma angiotensinogen levels
were similar in SD rats and TGRs, except at eight weeks, Ang peptide levels of diabetic TGRs were similar to
those of nondiabetic and diabetic SD rats. In contrastwhen angiotensinogen levels were lower in diabetic
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Table 2. Plasma levels of glucose, renin, prorenin, angiotensinogen, ACE, and NEP of non-diabetic and diabetic SD rats and TGR
Duration of diabetes weeks
4 8
Parameter SD TGR SD TGR
Plasma glucose mm
Non-diabetic 5.660.4 5.760.5 ND ND
Diabetic 15.060.9b 17.060.9b 18.961.0 18.1 61.1
Plasma renin mGU/ml
Non-diabetic 0.1060.01 0.1660.01d 0.0960.01 0.36 60.18c
Diabetic 0.1960.05 0.1560.03 0.1960.06 0.62 60.17d
Plasma prorenin mGU/ml
Non-diabetic 0.1560.01 5.660.4d 0.1560.02 9.2 60.2d
Diabetic 0.1460.02 6.360.9d 0.4360.04b 24.063.2b,d
Plasma prorenin/total renin ratio %
Non-diabetic 6263 9761d 6166 97 62d
Diabetic 5068 9761d 7364 98 61d
Plasma angiotensinogen pmol/ml
Non-diabetic 407613 407616 467623 456 624
Diabetic 397624 335629a 337619b 286615b,c
Plasma ACE nmol/ml/min
Non-diabetic 8064 7765 7963 64 64c
Diabetic 10565b 6566d 8465 11567b,d
Plasma NEP nmol/ml/min
Non-diabetic 0.2160.01 0.2560.02 0.2160.02 0.23 60.01
Diabetic 0.2360.01 0.2760.04 0.2460.01 0.25 60.01
Values are expressed as means 6 sem; N 5 6 to 10 Abbreviations are: Sprague Dawley (SD), transgenic m(Ren-2)27 rat (TGR), Goldblatt unit (GU), angiotensin
converting enzyme (ACE), neural endopeptidase (NEP).
a P , 0.05, b P , 0.01, in comparison with respective non-diabetic group of the same duration
c P , 0.05, d P , 0.01, in comparison with respective SD rats of the same duration
to the increased plasma ACE levels of diabetic rats, Tissue bradykinin peptides
diabetes did not modify the plasma Ang II/Ang I ratio A comparison of the levels of BK-(1-9) and its inactive
of either SD rats or TGRs. metabolite BK-(1-7) in tissues of SD rats and TGRs
showed lower BK-(1-7) levels in kidney, adrenal gland,
Tissue angiotensin peptides and heart, and lower BK-(1-9) levels in heart of TGRs at
eight weeks (Fig. 3 and Table 4). The BK-(1-7)/BK-(1-9)In agreement with the increased plasma renin and Ang
ratio provides an index of the rate of conversion ofpeptide levels in TGRs, Ang II levels were higher in kid-
BK-(1-9) to BK-(1-7). The BK-(1-7)/BK-(1-9) ratios ofney, adrenal gland, and aorta of nondiabetic TGRs than
TGRs were less than those of SD rats in kidney and aortain nondiabetic SD rats (Fig. 2 and Table 3). However,
at four and eight weeks and in adrenal gland at eightAng II levels were not elevated in the heart of TGRs
weeks, consistent with reduced metabolism of BK-(1-9)(Table 3). The increased renal Ang II levels in nondiabetic
to BK-(1-7) in these tissues of TGRs (Fig. 3 and Table 4).TGRs were associated with a reduced Ang I level and an
Diabetes increased BK peptide levels in kidney, aorta,increased Ang II/Ang I ratio at eight weeks (Fig. 2).
and heart, but not in adrenal gland (Fig. 3 and Table 4).Similar to the effects seen in plasma, diabetes did not
For kidney, diabetes increased both BK-(1-7) andmodify tissue Ang II levels in SD rats, but reduced Ang
BK-(1-9) levels at four weeks but not at eight weeks (Fig.
II levels in kidney and adrenal gland at four and eight 3). These increases were not statistically significant when
weeks and in aorta at four weeks in TGRs (Fig. 2 and SD rats and TGRs were analyzed separately, but achieved
Table 3). Thus, diabetes tended to “normalize” the in- statistical significance when SD rats and TGRs were ana-
creased tissue Ang II levels of TGRs. Diabetes did not lyzed together by two-way analysis of variance [BK-(1-7):
modify Ang II levels in heart (Table 3). Diabetes reduced F1,36 5 6.151, P 5 0.018; BK-(1-9): F1,36 5 6.553, P 5 0.015].
Ang I levels in kidney of SD rats at eight weeks (Fig. 2). For aorta, diabetes increased BK-(1-7) levels in both SD
For adrenal gland, aorta, and heart, Ang I levels were rats and TGRs and BK-(1-9) levels in TGRs at eight
close to or below the limit of detection (adrenal gland, weeks (Table 4). For heart, diabetes increased BK-(1-7)
,50 fmol/g; aorta, ,20 fmol/g; heart, ,2 fmol/g). The levels in SD rats and TGRs at both four and eight weeks
reduction of kidney Ang II levels of TGR by diabetes and BK-(1-9) levels in SD rats and TGRs at four weeks
was associated with a decrease in the Ang II/Ang I ratio and SD rats at eight weeks (Table 4). Diabetes did not
influence the BK-(1-7)/BK-(1-9) ratio, except for an in-in this tissue at both four and eight weeks (Fig. 2).
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Fig. 1. Plasma levels of angiotensin (Ang) II
(A, B) and Ang I (C, D), and plasma Ang II/Ang
I ratio (E, F) in nondiabetic (h) and diabetic
(j) Sprague Dawley (SD) rats and transgenic
(mRen-2)27 (TGR) rats at four- and eight-weeks
post-streptozotocin (STZ) or vehicle. Values
are expressed as means 6 sem (N 5 10); *P ,
0.05, **P , 0.01 diabetic vs. corresponding non-
diabetic rats; †P , 0.05, ††P , 0.01 TGRs vs.
corresponding SD rats.
crease in BK-(1-7)/BK-(1-9) ratio in kidney of SD rats at krein activity in diabetes, rather than to reduced kinin
metabolism by ACE or NEP. Further evidence that theeight weeks (Fig. 3).
increased BK-(1-9) levels were not consequent to reduced
metabolism was the failure of diabetes to reduce plasma
DISCUSSION levels of NEP and ACE. Our finding of increased BK-
The main findings of this study were the increased (1-9) levels in diabetes is in agreement with previous
tissue BK-(1-7) and BK-(1-9) levels in diabetic SD rats reports of increased renal tissue kallikrein levels and
and TGRs, whereas Ang II levels were similar in nondia- urinary kallikrein and kinin excretion in diabetic rats
betic and diabetic SD rats, and diabetes reduced the ele- and humans treated chronically with insulin [28–30].
vated Ang II levels of nondiabetic TGRs to the levels of The early years of diabetes are characterized by in-
nondiabetic and diabetic SD rats. The parallel increases creased flow and pressure in the glomerular, retinal, and
in levels of BK-(1-9) and its metabolite BK-(1-7), without cutaneous capillary circulations [31]. Consistent with a
a decrease in the BK-(1-7)/BK-(1-9) ratio, were consistent generalized vasodilation is the increased blood volume
relative to body weight in STZ diabetic rats [5]. Kininswith increased kinin formation caused by increased kalli-
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Fig. 2. Kidney levels of Ang II (A, B) and Ang
I (C, D), and kidney Ang II/Ang I ratio (E, F)
in nondiabetic (h) and diabetic (j) SD rats and
TGRs at four- and eight-weeks post-STZ or
vehicle. Values are expressed as means 6 sem
(N 5 10); *P , 0.05, **P , 0.01 diabetic vs.
corresponding nondiabetic rats; †P , 0.05 TGRs
vs. corresponding SD rats.
are potent endothelium-dependent vasodilators that modynamic abnormalities are implicated in the patho-
genesis of the glomerulopathy that eventually developsstimulate an endothelial release of nitric oxide and pros-
taglandins [8]. If this finding of increased BK-(1-9) levels in this disorder [16], although there is uncertainty con-
cerning the role of glomerular hyperfiltration in the de-in kidney, aorta, and heart represents a generalized phe-
nomenon, it suggests an important role for BK-(1-9) velopment of nephropathy in humans [33]. The increased
microvascular flow is due to reduced precapillary andin the vasodilation of diabetes and the pathogenesis of
diabetic vascular disease. postcapillary resistance, whereas the increased capillary
pressure implies a relative increase in postcapillary resis-A state of glomerular hyperfiltration has been consis-
tently demonstrated in patients with newly diagnosed tance [31]. Increased kinin levels may contribute to the
increased microvascular flow, and the relative increaseIDDM [1–4], as well as in early stages of experimental
diabetes in animals [5–7, 32]. In the latter, this hyperfil- in postcapillary resistance may be due to an increased
renovascular sensitivity to Ang II in diabetes [34, 35].tration was shown to result from concomitant elevations
in glomerular plasma flow and mean glomerular capillary Consistent with this suggested role for Ang II in modulat-
ing postcapillary resistance, AT1 receptor antagonismhydraulic pressure [5–7, 32]. These early glomerular he-
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Table 3. Ang II levels in adrenal, aorta, and heart of non-diabetic and diabetic SD rats and TGR
Duration of diabetes weeks
4 8
Parameter SD TGR SD TGR
Adrenal Ang II fmol/g
Non-diabetic 13166180 22986142d 11166174 16486139c
Diabetic 14056238 8166133b,c 7456119 12086140a,c
Aorta Ang II fmol/g
Non-diabetic 4769 10667d 2364 4267c
Diabetic 50610 6168b 3369 56615
Heart Ang II fmol/g
Non-diabetic 9.662.1 13.962.7 10.1 61.2 11.562.1
Diabetic 9.061.4 9.361.9 8.1 61.8 13.662.4
Values are expressed as means 6 sem; N 5 9 to 10. Abbreviations are: Sprague Dawley (SD), transgenic m(Ren-2)27 rat (TGR), angiotensin II (Ang II).
a P , 0.05, b P , 0.01, in comparison of diabetic and corresponding non-diabetic rats
c P , 0.05, d P , 0.01, in comparison with respective SD rats of the same duration
selectively normalized the elevated glomerular capillary thereby unaffected by B2 receptor antagonism. These
data indicate a need to investigate the expression of B1hydraulic pressure and ultrafiltration coefficient in the
diabetic kidney [36]. Other actions of BK-(1-9) that may and B2 receptors in diabetes and the role of kinins in the
initiation of diabetic microvascular disease.contribute to diabetic renal disease include the stimula-
tion of mesangial cell proliferation, an effect potentiated The mechanisms of kinin generation are complex and
may involve the participation of tissue kallikrein, plasmaby insulin, and the stimulation of collagen production
by mesangial cells, an effect inhibited by insulin [37]. kallikrein, and kallikrein-independent mechanisms [43].
Moreover, the regulation of kallikrein activity is complexSeveral studies addressed the role of kinins in diabetes
by administering either the nonspecific kallikrein inhibi- and may involve kallistatin [44] and other inhibitors and
activators of kallikrein. Further experiments are requiredtor aprotinin or antagonists of the type 2 BK-(1-9) (B2)
receptor. The administration of aprotinin, or a first gen- to elucidate the specific tissue compartments where kinin
levels were increased and the mechanisms responsibleeration B2 receptor antagonist D-Arg,[Hyp3,Thi5,8,D-
Phe7]-BK-(1-9), lowered renal blood flow and the GFR for the increased BK levels observed in tissues of diabetic
rats in this study.[28, 30, 38], suggesting a contribution by an altered renal
kallikrein-kinin system to the development of glomeru- Previous studies found either suppressed or normal
plasma renin levels [10, 18], suppressed plasma angioten-lar hypertension [39]. However, there are conflicting re-
ports of the effects of the second-generation B2 receptor sinogen levels [45], and normal plasma Ang II levels in
diabetes [32, 38]. Diabetes has variable effects on renalantagonist HOE 140 in diabetes. An acute administration
of HOE 140 had no effect on GFR, renal plasma flow, levels of renin, angiotensinogen, and ACE, although Ang
II receptors are reduced in diabetic kidney [10, 45]. An-filtration fraction, or sodium excretion in STZ diabetic
rats [38, 40], although acute HOE 140 administration derson, Jung and Ingelfinger found increased levels of
renin protein and renin and angiotensinogen mRNA anddid reduce GFR in ACE inhibitor-treated diabetic rats
[38]. Moreover, Allen et al found no effect of 24-week reduced ACE levels in diabetic kidney [36]. Immunocy-
tochemical studies revealed that whereas proximal tubuleHOE 140 administration on albuminuria or glomerular
ultrastructure in STZ diabetic rats [17]. Similarly, Rum- ACE was reduced in diabetic kidney, ACE immuno-
staining was increased in glomeruli and renal vasculatureble, Komers, and Coopers found no effect of three-week
HOE 140 administration on mesenteric vascular hyper- [36, 46]. Kennefick et al and Vora et al reported normal
renal Ang II levels in diabetic rats, in agreement withtrophy in STZ-diabetic rats [18]. By contrast, a chronic
administration of HOE 140 reduced diuresis and protein- these findings [34, 38].
Both ACE inhibitors and AT1 receptor antagonistsuria in STZ-diabetic mice, without effect on glycemia or
body weight [41]. Responsiveness to B2 receptor antago- have renoprotective effects and reduce vascular hyper-
trophy in diabetes [14–18, 38, 40]. Although kinins arenism may depend on the stage of diabetes, in that second-
ary structural changes of the vasculature may prevent implicated in mediating some of these effects of ACE
inhibitors [18, 38, 40], the renoprotective and antihyper-response to B2 antagonism. Furthermore, hyperglycemia
may blunt the response to increased kinin levels by con- trophic effects of AT1 receptor antagonists indicate that
Ang II contributes to the vascular abnormalities of dia-tributing to defective endothelial nitric oxide production
in diabetes [35, 42]. Moreover, kinins may act through betes [17, 18]. The finding of normal renal Ang II levels
in diabetic kidney does not exclude a role for this peptidethe type 1 BK-(1-9) (B1) receptor, and their effects are
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Fig. 3. Kidney levels of bradykinin (BK) BK-
(1-7) (A, B) and BK-(1-9) (C, D), and kidney
BK-(1-7)/BK-(1-9) ratio (E, F) in nondiabetic
(h) and diabetic (j) SD rats and TGRs at four-
and eight-weeks post-STZ or vehicle. Values are
expressed as means 6 sem (N 5 10); *P , 0.05,
**P , 0.01 diabetic vs. corresponding nondia-
betic rats; †P , 0.05, ††P , 0.01 TGRs vs.
corresponding SD rats. For the BK-(1-7) and
BK-(1-9) levels at four weeks, the differences
between nondiabetic and diabetic rats were not
statistically significant when SD rats and TGRs
were analyzed separately, but were statistically
significant when SD rats and TGRs were ana-
lyzed together by two-way ANOVA.
in diabetic renal disease. Diabetes is associated with in- TGR is not due to BK-(1-9) and Ang II levels that differ
from those of diabetic SD rats. The cause of the acceler-creased renal sensitivity to Ang II in rats [34, 35] but not
in humans [47]. The increased renovascular sensitivity to ated glomerulosclerosis of diabetic TGRs remains un-
clear but may result from the additive effects of elevatedAng II in diabetic rats, despite reduced renal Ang II
receptor levels [10, 45], may be due, in part, to the inhibi- levels of BK-(1-9), “normal” levels of Ang II, induction
of other cytokine pathways by these two peptides, andtion by hyperglycemia of nitric oxide production by the
renal vasculature [35]. In contrast to the reduction in the hemodynamic effects of the TGR phenotype. In sep-
arate studies, we showed that both the ACE inhibitorAng II receptor number in kidney, diabetes is associated
with increased numbers of Ang II receptors in heart, perindopril and the AT1 antagonist valsartan normalized
blood pressure, prevented accelerated glomerulosclero-adrenal gland, and liver [45].
Our finding of similar kinin levels in SD rats and TGRs sis, and attenuated the changes in renal function in dia-
betic TGRs (Kelly, Cooper, Skinner, Wilkinson-Berka,and “normalization” of Ang II levels in diabetic TGR
suggests that the accelerated glomerulopathy of diabetic manuscript in preparation) [20], suggesting that “normal”
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Table 4. BK-(1-7) and BK-(1-9) levels and BK-(1-7)/BK-(1-9) ratio in adrenal, aorta,
and heart of non-diabetic and diabetic SD rats and TGR
Duration of diabetes weeks
4 8
Parameter SD TGR SD TGR
Adrenal BK-(1-7) fmol/g
Non-diabetic 151632 248671 217631 119 619c
Diabetic 150623 176639 323673 176 634
Adrenal BK-(1-9) fmol/g
Non-diabetic 146635 271671 202636 161 630
Diabetic 106610 179643 235651 196 632
Adrenal BK-(1-7)/BK-(1-9) ratio fmol/fmol
Non-diabetic 1.1560.12 0.8560.13 1.1260.10 0.78 60.10d
Diabetic 1.4960.21 1.0460.12 1.3860.11 0.85 60.05d
Aorta BK-(1-7) fmol/g
Non-diabetic 4768 46611 44610 28 66
Diabetic 69617 62617 108625a 73617b
Aorta BK-(1-9) fmol/g
Non-diabetic 3367 65616 40611 36 69
Diabetic 4768 79624 62612 91 614b
Aorta BK-(1-7)/BK-(1-9) ratio fmol/fmol
Non-diabetic 2.1160.66 0.9060.20c 1.3860.26 1.11 60.27
Diabetic 1.5160.25 0.8260.07c 1.9660.36 0.75 60.08d
Heart BK-(1-7) fmol/g
Non-diabetic 2264 1862 2663 17 62c
Diabetic 4166a 3465b 62611b 34611a,d
Heart BK-(1-9) fmol/g
Non-diabetic 2368 1963 3265 23 64
Diabetic 69627a 59615a 84620a 3164d
Heart BK-(1-7)/BK-(1-9) ratio fmol/fmol
Non-diabetic 1.2960.12 1.0460.12 1.0160.19 0.86 60.09
Diabetic 0.9160.14 0.9460.33 0.8660.08 1.16 60.27
Values are expressed as means 6 sem; N 5 10. Abbreviations are: Sprague Dawley (SD), transgenic m(Ren-2)27 rat (TGR), bradykinin-(1-7) [BK-(1-7)], bradykinin-
(1-9) [BK-(1-9)].
a P , 0.05, b P , 0.01, in comparison of diabetic and corresponding non-diabetic rats
c P , 0.05, d P , 0.01, in comparison with respective SD rats of the same duration
Ang II levels have a pathogenic role in diabetic renal gressive nephropathy of diabetic TGR was not associated
with BK-(1-9) and Ang II levels that differed from thosedisease in this model. Moreover, the renal Ang system
of diabetic SD rats.is compartmentalized, and the “normal” renal Ang II
levels measured in this and other studies may mask in-
creased Ang II levels in specific renal compartments such ACKNOWLEDGMENTS
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APPENDIXIn conclusion, diabetes was associated with elevated tis-
sue levels of BK-(1-9) and “normal” circulating and tissue Abbreviations used in this article are: ACE, angiotensin converting
enzyme; Ang, angiotensin; AT1 receptor, type 1 angiotensin II recep-levels of Ang II. The increased BK-(1-9) levels were
tor; B1 receptor, type 1 bradykinin receptor; B2 receptor, type 2 brady-
evidence for the participation of this peptide in the vascu- kinin receptor; BK, bradykinin; GFR, glomerular filtration rate; GTC/
TFA, 4 mol/liter guanidine thiocyanate, 1% trifluoroacetic acid inlar abnormalities of diabetes. However, the rapidly pro-
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water; HPLC, high-performance liquid chromatography; IDDM, insu- sin and bradykinin peptides in the TGR (mRen-2)27 rat. Hyperten-
sion 25:1014–1020, 1995lin-dependent diabetes mellitus; NEP, neutral endopeptidase 24.11;
RIA, radioimmunoassay; SD, Sprague-Dawley; STZ, streptozotocin; 20. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner
SL: A new model of diabetic nephropathy with progressive renalTGR (mRen-2)27 rats, Sprague Dawley rats transgenic for the mouse
Ren-2 gene. impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int
54:343–352, 1998
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